For healthcare professionals only

(linagliptin) 5 mg tablets

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland

T2Discussions:

Trending Topics

Welcome to this resource hub for the T2Discussions: Trending Topics events and accompanying materials. This website has been designed to provide you with details of upcoming webinars which may be of relevance to your clinical practice, and to make available additional materials to supplement your ongoing education and development. The website also includes on-demand videos of webinars which you may have missed. Throughout this website, the events and materials listed will focus particularly on the potential role of the dipeptidyl peptidase-4 (DPP-4) inhibitor Trajenta® (linagliptin) in the management of adults with type 2 diabetes. Please click on the tabs below to visit the pages of this website. Updates and additional materials will be added to this website on a regular basis, so do bookmark this site and revisit us. We hope that you will find the events and resources useful in your everyday clinical practice.

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
  • monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
  • in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

Request a call

Request a call from a Boehringer Ingelheim representative

Sign up

You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI’s products, services and events
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960, Fax: +44 1344 742661, or by e-mail: [email protected] (IRE).

PC-GB-106627 | March 2022

(linagliptin) 5 mg tablets

©2018-2022 Boehringer Ingelheim GmbH All rights reserved.

(linagliptin) 5 mg tablets

This promotional website has been developed, organised and funded by Boehringer Ingelheim.

Prescribing information for Great Britain and Northern Ireland

T2Discussions:

Trending Topics

Welcome to this resource hub for the T2Discussions: Trending Topics events and accompanying materials. This website has been designed to provide you with details of upcoming webinars which may be of relevance to your clinical practice, and to make available additional materials to supplement your ongoing education and development. The website also includes on-demand videos of webinars which you may have missed. Throughout this website, the events and materials listed will focus particularly on the potential role of the dipeptidyl peptidase-4 (DPP-4) inhibitor Trajenta® (linagliptin) in the management of adults with type 2 diabetes. Please click on the tabs below to visit the pages of this website. Updates and additional materials will be added to this website on a regular basis, so do bookmark this site and revisit us. We hope that you will find the events and resources useful in your everyday clinical practice.

Prescribing information for Great Britain and Northern Ireland

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:

Request a call

Request a call from a Boehringer Ingelheim representative.

Sign up

You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI’s products, services and events.

The content has been reviewed and approved by the sponsoring company prior to publication. Editorial support for this website has been provided by OmniaMed Communications.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone)

PC-GB-105752 | December 2021

(linagliptin) 5 mg tablets

©2018-2021 Boehringer Ingelheim GmbH All rights reserved.

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

This link will take you to a site not operated by the Boehringer Ingelheim and Lilly Diabetes Alliance. The Alliance is not responsible for the content of any linked site.
This link will take you to a site not operated by the Boehringer Ingelheim and Lilly Diabetes Alliance. The Alliance is not responsible for the content of any linked site.